osi-930
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2006 (NCT00513851)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Vascular endothelial growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12- Mol. weight
- 443.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1614710 ↗
Also known as
- n-(4-trifluoromethoxyphenyl)3-((quinolin-4-ylmethyl)amino)thiophene-2-carboxamide
- osi930
- osi 930
- osi-930
- osi-930
- osi-930
- osi-930
- osi-930
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00603356 | Phase 1 | Nov 1, 2007 | Astellas, OSI Pharmaceuticals |
| NCT00513851 | Phase 1 | Apr 1, 2006 | Astellas, OSI Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 2 | 2 | 1 | 2006 |
| OSI Pharmaceuticals | For profit | 2 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1